The identification of chronic kidney disease (OR = 2.8) and antihypertensive medication burden (OR = 1.8) as independent risk factors for elevated NT-proBNP provides insights into the patient populations most likely to benefit from biomarker screening. The gene discussed is NPPB; the disease is chronic kidney disease.